jRCT1030230687进行中（未招募）不适用
Study on clinicopathological characteristics and prognosis of ER-low positive breast cancer using National Clinical Database-Breast Cancer Registry (ER low positive breast cancer in NCD)
NA0 个研究点目标入组 200,000 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200,000
- 主要终点
- Disease-free survival
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- No limit 至 No limit（—）
- 性别
- Female
入选标准
- •Patients with primary breast cancer registered in the NCD
- •Patients with Stage I-III breast cancer who have undergone surgery
排除标准
- •non-invasive carcinoma (Tis)
- •Stage IV at diagnosis
- •Metastatic or recurrent breast cancer
- •Occult breast cancer (T0, TX)
- •HER2-positive breast cancer (immunostaining or FISH)
- •Male breast cancer
- •Synchronous or non-synchronous bilateral breast cancer
- •Preoperative radiotherapy cases
结局指标
主要结局
Disease-free survival
with and without perioperative endocrine therapy and chemotherapy in tumors with 1%<=ER<10
Breast Cancer Specific Survival
with and without perioperative endocrine therapy and chemotherapy in tumors with 1%<=ER<10
Overall Survival
with and without perioperative endocrine therapy and chemotherapy in tumors with 1%<=ER<10
次要结局
- Disease-free survival
- Breast Cancer Specific Survival
- Overall Survival
- Clinico-pathological background
研究者
相似试验
已完成
不适用
To study clinical profile and outcome of lung cancer patients.CTRI/2018/03/012791SAFDARJUNG HOSPITAL AND VMMCNEW DELHI312
尚未招募
不适用
Analysis of clinicopathologic characteristics, carcinogenic mechanisms and genetic abnormality in colorectal tumors with MSI including Lynch syndrome.ynch syndrome Colorectal tumorJPRN-UMIN000025142Tokushima University Hospital, Department of Gastroenterology and Oncology20
尚未招募
不适用
IgA Nephropathy, a growing concern.CTRI/2019/05/019117Kasturba medical college
尚未招募
不适用
Endometrial cancer - factors affecting disease recurrenceCTRI/2021/04/032663Amrita Institute
尚未招募
Unknown
Multicentric study on outcome of treatment of osteosarcoma in India, conducted by Indian Musculo Skeletal Oncology SocietyCTRI/2023/05/053100Indian Musculo Skeletal Oncology Society (IMSOS)